|
EP0656786B2
(de)
|
1992-05-19 |
2014-04-23 |
Novogen Research Pty Ltd |
Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
AUPO203996A0
(en)
|
1996-08-30 |
1996-09-26 |
Novogen Research Pty Ltd |
Therapeutic uses
|
|
GT199800127A
(es)
*
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
|
EP1063991A1
(de)
*
|
1998-03-17 |
2001-01-03 |
Warner-Lambert Company Llc |
Statin-matrix metalloproteinase inhibitoren als kombinationtherapeutica
|
|
WO2000038721A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
AU2007200367B2
(en)
*
|
1999-02-06 |
2010-04-08 |
Astrazeneca Ab |
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
|
|
GB0001662D0
(en)
|
1999-02-06 |
2000-03-15 |
Zeneca Ltd |
Pharmaceutical compositions
|
|
DK1216038T3
(da)
|
1999-08-30 |
2005-12-27 |
Sanofi Aventis Deutschland |
Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
|
|
AUPQ266199A0
(en)
|
1999-09-06 |
1999-09-30 |
Novogen Research Pty Ltd |
Compositions and therapeutic methods involving isoflavones and analogues thereof
|
|
DE19944803A1
(de)
*
|
1999-09-20 |
2001-03-29 |
Bayer Ag |
Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
|
|
WO2001022976A2
(en)
|
1999-09-24 |
2001-04-05 |
Vasogen Ireland Limited |
Combination of a statin and ex-vivo treated blood for treating artheroclerosis
|
|
FR2803525B1
(fr)
*
|
2000-01-06 |
2002-05-03 |
Sod Conseils Rech Applic |
Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
GB2361185A
(en)
|
2000-04-10 |
2001-10-17 |
Nicholas J Wald |
Pharmaceutical formulation for the prevention of cardiovascular disease
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
AR032758A1
(es)
|
2000-07-19 |
2003-11-26 |
Novartis Ag |
Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
|
|
AU2001284413A1
(en)
*
|
2000-08-30 |
2002-03-13 |
Sankyo Company Limited |
Medicinal compositions for preventing or treating heart failure
|
|
US7018649B2
(en)
*
|
2000-10-23 |
2006-03-28 |
Euro-Celtique, S.A. |
Felodipine transdermal device and methods
|
|
US8168616B1
(en)
*
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
AUPR255401A0
(en)
*
|
2001-01-16 |
2001-02-08 |
Novogen Research Pty Ltd |
Regulation of lipids and/or bone density and compositions therefor
|
|
HU230253B1
(hu)
|
2001-01-26 |
2015-11-30 |
Merck Sharp & Dohme Corp |
Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
DK1355644T3
(da)
|
2001-01-26 |
2006-10-23 |
Schering Corp |
Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
|
|
AUPR363301A0
(en)
|
2001-03-08 |
2001-04-05 |
Novogen Research Pty Ltd |
Dimeric isoflavones
|
|
US20030149010A1
(en)
*
|
2001-07-19 |
2003-08-07 |
Keller Bradley T. |
Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
|
|
PE20030324A1
(es)
*
|
2001-07-31 |
2003-04-03 |
Warner Lambert Co |
Composiciones farmaceuticas de amlodipina y atorvastatina
|
|
US6852737B2
(en)
*
|
2001-08-06 |
2005-02-08 |
Recordati Ireland Limited |
Crude and crystalline forms of lercanidipine hydrochloride
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
JP2005504091A
(ja)
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
CA2490636A1
(en)
*
|
2002-06-20 |
2003-12-31 |
The Governors Of The University Of Alberta |
Dichloroacetate in combination with cardioprotective or hemodynamic drugs
|
|
JP2005533822A
(ja)
*
|
2002-06-27 |
2005-11-10 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
臭化水素酸カルベジロール
|
|
MXPA04012923A
(es)
*
|
2002-06-27 |
2005-03-31 |
Sb Pharmco Inc |
Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
|
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
|
GB0221579D0
(en)
*
|
2002-09-17 |
2002-10-23 |
Pfizer Ltd |
Combinations of atorvastatin and, adrenergic receptor antagonists
|
|
JP2006504800A
(ja)
*
|
2002-10-16 |
2006-02-09 |
レコーダチ アイルランド リミテッド |
リシノプリル／レルカニジピンの組み合わせ治療
|
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
JP4589919B2
(ja)
|
2003-03-07 |
2010-12-01 |
シェーリング コーポレイション |
高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
|
CA2517571C
(en)
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
GB0322552D0
(en)
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
|
EP1686967A4
(de)
*
|
2003-11-25 |
2012-08-08 |
Smithkline Beecham Cork Ltd |
Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
|
|
CA2547137A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Sb Pharmco Puerto Rico Inc. |
Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
|
|
JP2007512372A
(ja)
*
|
2003-11-25 |
2007-05-17 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
カルベジロール塩、対応する組成物、送達および／または治療方法
|
|
KR20050092519A
(ko)
*
|
2004-03-16 |
2005-09-22 |
화이자 인코포레이티드 |
아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
|
|
US20070191438A1
(en)
*
|
2004-04-06 |
2007-08-16 |
Rohrer Susan P |
Methods for the treatment of hypertension
|
|
DE602005025755D1
(de)
|
2004-06-04 |
2011-02-17 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
|
ES2342090T3
(es)
*
|
2004-08-25 |
2010-07-01 |
Essentialis, Inc. |
Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
|
|
BRPI0607142A2
(pt)
*
|
2005-02-17 |
2009-08-11 |
Chiesi Farma Spa |
combinações terapêuticas de manidipina e uma estatina, seu uso e um kit
|
|
EP2000137B1
(de)
*
|
2006-03-29 |
2015-10-21 |
Kowa Company, Ltd. |
Mittel zur triglyzeridsenkung und mittel gegen hyperinsulinismus
|
|
US8642083B2
(en)
*
|
2006-10-30 |
2014-02-04 |
Hanall Biopharma Co., Ltd. |
Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
|
|
KR101209319B1
(ko)
|
2008-04-29 |
2012-12-06 |
한올바이오파마주식회사 |
안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
|
|
CZ2008740A3
(cs)
*
|
2008-11-24 |
2010-01-06 |
Zentiva, A.S. |
Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
|
|
MA33056B1
(fr)
*
|
2009-01-23 |
2012-02-01 |
Hanmi Holding Co Ltd |
Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
|
|
SI23149A
(sl)
*
|
2009-09-21 |
2011-03-31 |
Silverstone Pharma |
Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
|
|
RU2481124C1
(ru)
*
|
2011-10-27 |
2013-05-10 |
Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" |
Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
|
|
CN102671198A
(zh)
*
|
2011-12-17 |
2012-09-19 |
东莞达信生物技术有限公司 |
一种降压降脂复方药及其制备方法
|
|
KR20140028971A
(ko)
*
|
2012-08-31 |
2014-03-10 |
한미약품 주식회사 |
아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
|
|
JP2016514125A
(ja)
*
|
2013-03-12 |
2016-05-19 |
エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
|
|
CN104173420A
(zh)
*
|
2013-05-20 |
2014-12-03 |
广州诺氏刘生物科技有限公司 |
一种治疗急性肾衰竭的药物
|
|
US10537546B2
(en)
|
2014-10-23 |
2020-01-21 |
Arena Pharmaceuticals, Inc. |
Method of treating conditions related to the PGI2 receptor
|
|
RU2724338C2
(ru)
*
|
2015-06-30 |
2020-06-23 |
Ханми Фарм. Ко., Лтд. |
Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
|
|
FR3040303B1
(fr)
*
|
2015-08-27 |
2019-04-05 |
Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger |
Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
|
|
CN105232555A
(zh)
*
|
2015-11-19 |
2016-01-13 |
哈尔滨圣吉药业股份有限公司 |
一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
|
|
AU2017274438A1
(en)
*
|
2016-06-02 |
2018-12-13 |
Ana Pharmaceuticals, Inc. |
Methods and compositions for treatment of hypercalciuria and nephrolithiasis
|
|
SI4101454T1
(sl)
|
2017-01-25 |
2024-10-30 |
The George Institute for Global Health |
Sestavki za uporabo pri zdravljenju hipertenzije
|
|
US12521380B2
(en)
|
2017-01-25 |
2026-01-13 |
The George Institute for Global Health |
Compositions for the treatment of hypertension
|
|
IL268997B2
(en)
|
2017-03-01 |
2023-09-01 |
Arena Pharm Inc |
Preparations containing pgi2 receptor agonists and processes for their preparation
|
|
EP3796902A1
(de)
|
2018-05-16 |
2021-03-31 |
Arena Pharmaceuticals, Inc. |
Zusammensetzungen mit pgi2-rezeptoragonisten und verfahren zu deren herstellung
|
|
AU2019309329B2
(en)
*
|
2018-07-26 |
2025-01-30 |
The George Institute for Global Health |
Compositions for the treatment of hypertension
|
|
CN112826937B
(zh)
*
|
2021-03-25 |
2022-03-22 |
山东大学齐鲁医院 |
艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用
|